1. Home
  2. LKFN vs CAPR Comparison

LKFN vs CAPR Comparison

Compare LKFN & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Lakeland Financial Corporation

LKFN

Lakeland Financial Corporation

HOLD

Current Price

$60.40

Market Cap

1.5B

Sector

Finance

ML Signal

HOLD

Logo Capricor Therapeutics Inc.

CAPR

Capricor Therapeutics Inc.

HOLD

Current Price

$28.05

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LKFN
CAPR
Founded
1872
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.3B
IPO Year
2009
2011

Fundamental Metrics

Financial Performance
Metric
LKFN
CAPR
Price
$60.40
$28.05
Analyst Decision
Hold
Strong Buy
Analyst Count
3
8
Target Price
$67.00
$41.38
AVG Volume (30 Days)
132.2K
1.0M
Earning Date
04-27-2026
01-01-0001
Dividend Yield
3.44%
N/A
EPS Growth
N/A
N/A
EPS
2.85
N/A
Revenue
$985,000.00
$22,270,465.00
Revenue This Year
$15.08
N/A
Revenue Next Year
$5.18
$17,308.50
P/E Ratio
$21.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$50.00
$4.30
52 Week High
$69.38
$40.37

Technical Indicators

Market Signals
Indicator
LKFN
CAPR
Relative Strength Index (RSI) 47.78 61.82
Support Level $59.67 $22.05
Resistance Level $62.50 $29.28
Average True Range (ATR) 1.82 1.82
MACD -0.22 0.46
Stochastic Oscillator 17.48 83.67

Price Performance

Historical Comparison
LKFN
CAPR

About LKFN Lakeland Financial Corporation

Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: